ReviewFrontiers in pharmacology2014
Application of insulin-like growth factor-1 in the treatment of inner ear disorders.
Review in Frontiers in pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Mesenchymal stem cells for sensorineural hearing loss: a systematic review of preclinical studies.Molecular biology reports · 2020Pooled it
- Galectin and Myc enable cochlear progenitor expansion in vitro and in vivo.bioRxiv : the preprint server for biology · 2026Article
- Time-Series Transcriptome Analysis of the Older Adult Mouse Cochlea After Noise-Induced Hearing Loss Reveals an Acute Immune Response and Recovery-Associated Pathways.Molecular neurobiology · 2025Article
- GPR83 protects cochlear hair cells against ibrutinib-induced hearing loss through AKT signaling pathways.Frontiers in medicine · 2025Article
- Interaction with IGF1 overrides ANXA2-mediated anti-inflammatory functions of IGFBP5Frontiers in immunology · 2024Article
- A Prospective Study Examining Audiometry Outcomes Following Teprotumumab Treatment for Thyroid Eye Disease.Thyroid : official journal of the American Thyroid Association · 2024Article
- The Adverse Effects Profile of Teprotumumab.The Journal of clinical endocrinology and metabolism · 2023Review
- Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?Journal of endocrinological investigation · 2022Article
- LRP1 mediates the IGF-1-induced GLUT1 expression on the cell surface and glucose uptake in Müller glial cells.Scientific reports · 2021Article
- Efficacy and Safety of Teprotumumab in Thyroid Eye Disease.Therapeutics and clinical risk management · 2021Review
- The effect of insulin-like growth factor 1 on the recovery of facial nerve function in a guinea pig model of facial palsy.The journal of physiological sciences : JPS · 2020Article
- [New progress of IGF-1 and allosteroid injection in the treatment of sudden deafness complicated with type 2 diabetes].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2020Review
- Growth factor and receptor malfunctions associated with human genetic deafness.Clinical genetics · 2020Review
- Defining the Inflammatory Microenvironment in the Human Cochlea by Perilymph Analysis: Toward Liquid Biopsy of the Cochlea.Frontiers in neurology · 2019Article
- Forgotten Fibrocytes: A Neglected, Supporting Cell Type of the Cochlea With the Potential to be an Alternative Therapeutic Target in Hearing Loss.Frontiers in cellular neuroscience · 2019Article
- Otoprotection to Implanted Cochlea Exposed to Noise Trauma With Dexamethasone Eluting Electrode.Frontiers in cellular neuroscience · 2019Article
- IGF-1, Inflammation and Retinal Degeneration: A Close Network.Frontiers in aging neuroscience · 2018Review
- Biological therapies in otology.HNO · 2017Review
- Article
- Autophagy resolves early retinal inflammation in Igf1-deficient mice.Disease models & mechanisms · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sensorineural hearing loss (SNHL) is considered an intractable disease, given that hair and supporting cells (HCs and SCs) of the postnatal mammalian cochlea are unable to regenerate. However, with progress in regenerative medicine in the 21st century, several innovative approaches for achieving regeneration of inner ear HCs and SCs have become available. These methods include stem cell transplantation, overexpression of specific genes, and treatment with growth factors. Insulin-like growth factor-1 (IGF-1) is one of the growth factors that are involved in the development of the inner ear. Treatment with IGF-1 maintains HC numbers in the postnatal mammalian cochlea after various types of HC injuries, with activation of two major pathways downstream of IGF-1 signaling. In the aminoglycoside-treated neonatal mouse cochlear explant culture, promotion of the cell-cycle in SCs as well as inhibition of HC apoptosis was observed in the IGF-1-treated group. Activation of downstream molecules was observed in SCs and, in turn, SCs contribute to the maintenance of HC numbers. Using comprehensive analysis of the gene expression, the candidate effector molecules of the IGF-1 signaling pathway in the protection of HCs were identified as Netrin1 and Gap43. Based on these studies, a clinical trial has sought to investigate the effects of IGF-1 on SNHL. Sudden SNHL (SSHL) that was refractory to systemic steroids was treated with IGF-1 in a gelatin hydrogel and the outcome was compared with a historical control of hyperbaric oxygen therapy. The proportion of patients showing hearing improvement was significantly higher in the IGF-1-treatment group at 24 weeks after treatment than in the control group. A randomized clinical trial is ongoing to compare the effect of IGF-1 treatment with that of intra-tympanic steroids for SSHL that is refractory to systemic steroids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.